Skip to main content
ANVS
NYSE Life Sciences

Annovis Q3 Loss Widens as R&D Hits $15.8M; DUET-AD Data Due March 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.94
Mkt Cap
$39.525M
52W Low
$0.616
52W High
$5.5
52W Position info
53% above low
Off High info
83% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ANVS sits 53% above its 52-week low of $0.616.

Summary

Annovis reported a $9.5 million Q3 net loss on R&D of $15.8 million and $2.8 million of cash at September 30; the $21.0 million November offering is expected to carry it to DUET-AD topline data in March 2027.


Key Events · Earnings and Guidance · ANVS

  • Q3 Net Loss of $9.5 Million

    Net loss was $9.5 million, or $0.22 per share, versus $7.3 million a year earlier; the nine-month loss reached $41.9 million.

  • R&D Spending More Than Doubles

    R&D expense was $15.8 million for the quarter versus $6.3 million a year earlier, and $44.5 million for the nine months versus $16.5 million.

  • Cash of $2.8 Million at Quarter-End

    Cash fell to $2.8 million from $19.5 million at December 31, 2025; the $21.0 million offering that closed November 6 is expected to fund operations through the DUET-AD 6-month readout.

  • DUET-AD Readout Set for March 2027

    Last patient, last visit of the 6-month treatment period is scheduled for December 31, 2026, database lock February 8, 2027, and topline results in March 2027.


Analysis · ANVS · Life Sciences

Cash burn is the story this quarter: R&D spending more than doubled to $15.8 million from $6.3 million a year earlier, and the nine-month operating loss reached $49.4 million against a $2.8 million cash balance at September 30. That balance is survivable only because the $21.0 million offering closed November 6, and management says it funds operations through the 6-month DUET-AD readout in March 2027 — leaving the company financed to exactly one binary event, with no cushion past it. The warrant liability jumping to $12.5 million is a non-cash mark-to-market tied to the higher share price, not new dilution or cash owed. The stock's path now hinges on the December 31 last-patient visit, the February 8 database lock, and March 2027 topline.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANVS was trading at $0.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $39.5M. The 52-week trading range was $0.62 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 06, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.8799
Real-time Price: $0.940 info
Change: +$0.0601 (+7%) info
Market Cap: $39.525M info
ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.940 info
Change: +$0.0711 (+8%) info
Market Cap: $39.525M info
ANVS
Nov 04, 2026, 5:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.940 info
Change: $0 (0%) info
Market Cap: $39.525M info
ANVS
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8507
Real-time Price: $0.940 info
Change: +$0.0893 (+10%) info
Market Cap: $39.525M info
ANVS
Nov 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.880
Real-time Price: $0.940 info
Change: +$0.060 (+7%) info
Market Cap: $39.525M info